Minimal residual disease (MRD) can be detected in the marrows of children undergoing chemotherapy either by flow cytometry or polymerase chain reaction. In this study, we used four-color flow cytometry to detect MRD in 1016 children undergoing therapy on Children's Oncology Group therapeutic protocols for precursor-B-cell ALL. Compliance was excellent, with follow-up samples received at the end of induction on nearly 95% of cases; sensitivity of detection at this time point was at least 1/10,000 in more than 90% of cases. Overall, 28.6% of patients had detectable MRD at the end of induction. Patients with M3 marrows at day 8 were much more likely to be MRD positive (MRD+) than those with M2 or M1 marrows. Different genetically defined groups of patients varied in their prevalence of MRD. Specifically, almost all patients with BCR-ABL had high levels of end-of-induction MRD. Only 8.4% of patients with TEL-AML1 were MRD+40.01% compared with 20.3% of patients with trisomies of chromosomes 4 and 10. Our results show that MRD correlates with conventional measures of slow early response. However, the high frequency of MRD positivity in favorable trisomy patients suggests that the clinical significance of MRD positivity at the end of induction may not be the same in all patient groups.
Introduction
Minimal residual disease (MRD) can be detected in many patients, who undergo therapy for acute lymphoblastic leukemia (ALL). [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] MRD may be detected at a sensitivity of at least 10
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either by molecular means, generally based on polymerase chain reaction (PCR) amplification of rearranged immunoglobulin (Ig) or T-cell receptor genes 13, 14, [16] [17] [18] [19] [20] or by multiparameter flow cytometry. 1, 2, [8] [9] [10] 15, [21] [22] [23] [24] [25] [26] The latter approach is based on the fact that leukemic cells express aberrant phenotypic combinations of antigens that are not present on normal bone marrow cells. 9, 22, [27] [28] [29] Both methods are generally recognized as useful, although they have different advantages and disadvantages. When optimally performed, molecular studies are more sensitive, and may require less material. However, flow cytometry is less expensive than molecular methods that rely on sequencing to detect clone-specific markers, and is rapid, with test results available within a few hours of sample receipt.
MRD detected using either method is an important prognostic factor in the outcome of children with ALL. 1, [5] [6] [7] [8] 13, 14, 26, [29] [30] [31] [32] MRD has been studied at multiple time points throughout treatment. These studies show that although patients are noted to be positive less frequently as treatment progresses, MRD has prognostic significance at several time points. MRD levels at the end of induction are highly prognostic. Since intensification of therapy after successful induction can improve the outcome of many patients with adverse prognostic features, 33 it is possible that a similar approach might benefit patients with MRD. For these reasons, we have chosen to focus our MRD studies on end-of-induction therapy.
Although MRD and other measures of early response to therapy [34] [35] [36] are important to prognosis, many other clinical and biological factors also affect outcome. Chromosome number and certain translocations also identify patients with good or poor prognoses. [37] [38] [39] [40] [41] Most studies of MRD have not had enough patients to determine the relation between the presence of residual leukemia and these other factors. Moreover, although MRD has been shown to be an independent prognostic factor in multivariate analysis, 1, 9, 14, 30 the precise relation between morphologic assessment of slow early response and MRD has been studied incompletely. In this report, we describe the relation between the end-of-induction MRD as detected by multiparameter flow cytometry and other known prognostic factors, in a series of more than 1000 children with precursor-Bcell ALL. We find that there is a significant correlation between end-of-induction MRD and day 8 morphologic assessment of marrow response. In addition, we find significant differences among MRD rates in genetically defined groups of patients, which suggest that the clinical significance of MRD at the end of induction may not be the same in all patient subgroups.
Materials and methods

Patient samples
The children in this study were enrolled on one of three ongoing treatment studies for childhood precursor-B ALL from April 2000 to January 2002. Enrollment was based on patients' NCI risk groups and the presence of specific molecular abnormalities, as shown in Table 1 . All patients were enrolled on the POG 9900 classification study, which required shipment of blood and bone marrow samples to reference laboratories at the University of New Mexico and the Johns Hopkins Medical Institutions. Patients with precursor-B-cell ALL, as confirmed by the Johns Hopkins laboratory, were categorized at the end of induction as low-, standard-, or high-risk based on modified age and white blood cell (WBC) criteria 42 and molecular studies performed at the University of New Mexico, as described below. These patients were enrolled on consolidation/continuation treatment protocols 9904, 9905, and 9906, respectively. All patients or their parents or guardians gave separate informed consent for the classification and treatment studies. Patients with precursor-B ALL enrolled on the classification study 9900 received induction therapy of three drugs (vincrinstine, dexamethasone, and L-asparaginase) or four drugs (vincristine, prednisone, L-asparaginase, and daunomycin) based on their NCI risk classification at diagnosis. Patients o1 year old, those with T-cell ALL, Burkitt's leukemia, Philadelphia chromosomepositive (Ph+(bcr-abl+)) ALL, or those who did not achieve first remission were not eligible for any of these studies.
Bone marrow was obtained at day 8 to determine morphologic response. Patients were classified as M1 (o5% blasts), M2 (5-24% blasts), and M3 (X25% blasts) by local institutions using standard morphologic criteria. Additionally, a blood sample at day 8 was obtained for flow cytometric studies of residual disease. At day 29 following induction therapy, bone marrow and blood samples were sent for MRD studies at both the New Mexico and Johns Hopkins reference laboratories. The MRD studies at New Mexico will be the subject of a separate report.
In 93% of cases, the specimen was processed within 24 h of obtaining the sample. The remaining 7% of specimens, ranged from 3 to greater than 5 days old. We found MRD somewhat less frequently (18 vs 28% overall) in these older samples. The distribution of cytogenetic abnormalities and of slow early responders by conventional morphology was the same in this 7% of patients as in the entire group. Experiments in which samples were stored in the laboratory showed a decrement in recovery with time in some but not all specimens. Thus, we cannot rule out some level of false negatives among the older specimens.
Flow cytometry
Diagnostic samples: Each sample received in the Johns Hopkins reference laboratory that had been classified as precursor-B-cell ALL was studied with a limited panel of antibodies in four-color flow cytometry to confirm the diagnosis, to identify phenotypes associated with particular translocations, as previously described, 27 and to define an abnormal phenotype for purposes of monitoring. In nearly 90% of cases, the two-tube panel CD20ÀFITC/CD10ÀPE/CD45-perCP/CD19ÀAPC and CD34ÀFITC/CD9ÀPE/CD45ÀperCP/CD19ÀAPC was sufficient for this purpose, and defined several abnormal phenotypes useful for monitoring for residual leukemia. In the remaining cases, additional markers including CD38, CD15, CD13, CD66b, CD22, or TdT were added to these combinations to further define an informative phenotype for monitoring. All antibodies were obtained from Becton Dickinson (San Jose, CA, USA) except for CD10 (Dako, Carpenteria, CA, USA) and CD66b, CD38, and TdT (Beckman-Coulter/Immunotech, Miami, FL, USA). Cases in which the local institutional diagnosis was not known were initially studied with a larger panel of antibodies to confirm lineage, and cases identified as precursor-B ALL were handled as described above.
Follow-up samples: Day 8 blood samples were processed by a modified stain-then-lyse procedure, usually using the single four-color tube that best discriminated normal and abnormal cells. Since most cases had low cell numbers, a procedure was developed using a buffy-coat-enriched specimen. Serum, buffy coat and the top of the red cell layer were obtained from a pelleted cell preparation, and the material resuspended and processed by our usual stain-then-lyse procedure. When the buffy-coat method was compared in 15 samples to a lyse-thenstain method using ammonium chloride, there was a high correlation (r ¼ 0.99 by linear regression analysis) in the percent of leukemic cells found, with a few samples showing superior recovery with the buffy-coat method. Day 29 marrow samples almost always had sufficient cells to process using standard methods, but in about 2% of samples, only sufficient material was available to run a single informative tube. In the remaining cases, at least two and in rare cases three different four-color tubes were assayed.
Stained samples were analyzed on a dual-laser FACSCAlibur flow cytometer (Becton-Dickinson, San Jose, CA, USA). In all cases, CD19-APC was used as a gating reagent. Generally 750 000 cells, with a minimum of 500 000 cells, were run through the flow cytometer for day 29 marrow samples. Only CD19-positive (CD19+) cells with low right-angle scatter were saved for further analysis. Debris was subtracted from the denominator based on examination of forward scatter vs side scatter displays. The total number of B cells, calculated as the percentage of CD19+ events divided by the total number of cells run through the cytometer, showed excellent agreement in all cases with the percent of CD19+ cells seen in a separate acquisition of 10 000-20 000 ungated events. This latter acquisition was also used to calculate the percent of mononuclear cells in the sample; granulocytes were excluded on displays of CD45 vs right-angle scatter, based on their intermediate density CD45 and high scatter. In some experiments, the combination CD45 and CD71 was used to identify 27 showing the expected pattern of antigen expression in normal B-cell development were used to screen samples for the presence of abnormal cell clusters in positions outside the normal areas. The percentage of MRD was determined by dividing the number of cells in an abnormal cluster by the total number of cells acquired. Based on prior experiments, it was determined that in most cases it was possible to recognize a cluster of as few as 15 events, if these were well defined and distinct from normal areas. This gives a theoretical sensitivity of 1/50 000 for cases with 750 000 events collected. However, because not every case achieved this ideal, we considered our operational sensitivity to be 1/10 000 (generally a minimum of 75 events, which was very easy to see) and most of our results are reported at this threshold. In about 7% of cases, we could only achieve a sensitivity estimated at 1/1000. Reasons for this included having too few cells for analysis or having very large numbers of normal B-cell precursors and a phenotype that showed partial or significant overlap between the leukemic and normal cells. In 6.6% of cases enrolled on one of the treatment studies, no day 29 marrow specimens were received, and 1.8% of samples were considered to have indeterminate results, usually because no abnormal phenotypes were determined at diagnosis. The number of uninformative cases is lower than that suggested by previous reports, 2 because in most cases there were very few or no normal B-cell precursors seen in day 29 marrows, something that has been previously noted. 9 Although we did not record the percentage of normal B-cell precursors in all cases, in a subset of 100 consecutive day 29 marrows we found nearly half (48%) to have no detectable normal B-cell precursors (ie no events in 750 000 cells), with a maximum number of 0.6% normal cells. Thus, in such cases, even a phenotype that might have fallen within the normal template boundaries could still easily be recognized as abnormal.
PCR testing and fluorescence in situ hybridization
Diagnostic samples of bone marrow and peripheral blood received at the University of New Mexico Cancer Center were processed by Ficoll-Hypaque density gradient centrifugation, followed by standard cell counting and viability studies. Aliquots of cells were allocated for DNA index analysis, fluorescence in situ hybridization (FISH), and PCR assays. Screening for common chromosomal translocations in pediatric ALL, including the t(9;22)/BCR-ABL, t(1;19)/E2A-PBX1, t(12;21)/ TEL-AML1, and t(4;11)/MLL-AF4 was performed by reversetranscription PCR following RNA extraction using standard methods. Post-PCR detection of specific RT-PCR products was confirmed by chemiluminescent Southern blot hybridization with junctional-region oligonucleotide probes. All pediatric samples with DNA indexes 41.0 had centromeric probe FISH testing performed for trisomies of chromosomes 4 and 10 to identify 'good-risk' hyperdiploid patients. Cells were cohybridized with centromere enumeration probes for chromosomes 4 (Spectrum Orange 
Statistics methods
This report is mostly descriptive. Associations involving MRD and other characteristics were analyzed by Pearson's w 2 or the Kruskal-Wallis test if the covariate had more than two (ordinal) categories. Association among MRD, day 8 blood, and day 8 bone marrow were performed by the Mantel-Haenszel test, for stratified two-by-two tables. In each case, one variable was stratified for analyzing the other two. All P-values are two-sided.
Results
Correlation of MRD and traditional risk factors
Overall, 225 of 1016 (22.1%) patients had bone marrows at the end of induction with MRD 40.01%. An additional 65 patients had detectable MRD at levels below 1/10 000 cells, for a total positivity rate of 28.6%. A total of 129 of 1016 (12.7%) patients had MRD levels greater than 0.1%. Among patients considered positive, the median percent positive was 0.069%.
MRD correlated significantly with risk group. NCI high-risk patients were significantly more likely to be MRD-positive (MRD+) than standard-risk patients. Of high-risk patients, 29.8% (n ¼ 325) were MRD+ 40.01%, compared with 18.5% of standard risk (n ¼ 690) (Po0.001 by w 2 analysis). At a cutoff of 0.1%, there were 22.8% high-risk patients positive, compared with 8.0% standard risk (Po0.001). The median percentage of leukemic cells among patients considered positive was nearly eight times higher (0.30 vs 0.041%) in NCI high-risk patients than in NCI standard-risk patients.
Relation between MRD and molecular genetic findings at diagnosis Table 2 shows the relation between MRD levels at the end of induction, and genetic lesions identified at diagnosis. Although patients with demonstrable bcr-abl were excluded from the therapeutic studies noted above, 18 patients with Ph+ ALL had material sent for MRD analysis at end of induction; 16 of 18 (89%) were positive, all with high (40.1%) levels of disease. Five of 38 patients (13.2%) with E2A-PBX1 ALL had MRD, and four of five had levels 40.1%. The most surprising findings, however, were that patients with favorable trisomies and those with TEL-AML1 translocations had substantially different levels of MRD detected, even though both are considered good-risk patients. At a threshold of 0.01%, 20.3% of patients with trisomies 4 and 10 were MRD+, compared with only 8.2% of TEL-AML1 patients; nearly 10% of good trisomy patients had high levels of MRD (40.1%) compared with 2.4% of those with TEL-AML1. It should also be noted that there was a similar relation in the morphologic response to therapy between the TEL-AML1 and the good trisomy patients; 24% of trisomies 4 and 10, but only 10% of TEL patients, had M3 marrows at day 8.
Correlation of end-of-induction marrow MRD and day 8 bone marrow morphology
Morphologic data on day 8 bone marrow samples were available for 936 patients with MRD data. Day 8 bone marrow morphology showed that 577 patients had M1 marrows, 157 patients had M2, and 202 had M3. As shown in Figure 1 , there was significant correlation between residual disease assessed by bone marrow morphology and day 29 MRD either at 0.1 or 0.01% (Po0.001 for both by Kruskal-Wallis analysis). However, the correlation was not perfect. Of rapid early responders with day 8 M1 marrows, 12% were MRD+ 40.01%, nearly half (5.5% overall) with high (40.1%) MRD. Similarly, only about half of patients with day 8 M3 marrows had detectable MRD at the end of induction.
Assessment of day 8 blood samples by flow cytometry
Owing to the known importance of early response to therapy, flow cytometric assessment also was performed at day 8 following initiation of therapy. At that time, most marrows are hypocellular, and it was reasoned that flow cytometric assessments of bone marrow would be inaccurate because of hemodilution, especially since the first aspirate of this marrow was invariably used for morphology. Accordingly, we used blood specimens at day 8, in the hope that this would provide a more accurate measurement. Overall, 553 of 909 (60.8%) patients had 40.01% leukemic cells detected in blood at day 8. The median value among positive patients was 0.37%; 44% of patients had 40.1% and 19.7% of patients 41%. We next determined whether day 8 marrow morphology or day 8 blood flow cytometry was a better predictor of bone marrow MRD at day 29. All three variables were satisfactorily measured in 824 patients. The results are shown in Table 3 . Day 8 marrow morphology and day 8 blood flow cytometry were independent factors predictive of day 29 bone marrow MRD. The associations among all three variables are significant, and stratification on any one shows that the other two are still significantly correlated (Po.001, Mantel-Haenszel test). Patients who had no detectable blood blasts by flow cytometry at day 8 were rarely MRD+ at day 29, even if they were M2 or M3 by morphology. However, patients positive by flow cytometry in the day 8 blood samples were nearly three times more likely to be MRD+ if they had 45% morphologically detectable blasts in the day 8 marrows. This suggests that while day 8 blood flow cytometry measurements cannot replace marrow assessment of early response, they might help to indicate which patients could benefit from marrow examination.
Discussion
Many studies over the past several years have suggested that the presence of MRD early in therapy for childhood ALL is a strong adverse prognostic factor. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [13] [14] [15] Although some of these studies demonstrated that MRD maintained prognostic significance in Cox-model multivariate analyses, these studies generally have not had enough patients to understand the relation between MRD and other risk factors, or to determine if there was any interaction among variables. That is, it is not clear if the prognostic significance of finding MRD is the same in all patient groups. In the current study, we investigated bone marrow MRD levels at the end of induction in more than 1000 children with precursor-B ALL, and correlated this to other known risk factors. This study is currently less than 3 years old, so we do not yet have outcome data. However, this preliminary report shows a strong correlation of MRD with other known poor-risk factors.
Overall, we detected bone marrow MRD by four-color flow cytometry at a level of 0.01% in approximately 22% of patients at the end of induction, with 12.7% having more than 0.1%. However, at the higher cutoff levels, nearly three times as many NCI high-risk patients were MRD+ compared with NCI standard-risk ones, suggesting that poor clearance of leukemic cells may explain high-risk characteristics. This interpretation is consistent with laboratory studies showing that MRD was correlated with poor in vitro prednisolone response. 43 Similarly, patients with slow early response, as assessed by examination of marrow morphology at day 8, also were far more likely to be MRD+ by flow cytometry at end of induction compared with 
Figure 1
Relationship of MRD and day 8 marrow morphology. The percentage of patients with MRD positivity at end of induction at both the 0.1 and 0.01% levels is plotted against marrow blast content based on morphologic examination of a day 8 marrow sample. At both levels MRD and blast content are positively associated. Minimal residual disease in childhood ALL MJ Borowitz et al rapid early responders. As it has been shown that slow early responders can be rescued following intensification of therapy, 44 there is cause for optimism that many patients with MRD at day 29 can be rescued by such intensification. The current study is designed to address this issue.
In addition to the widely known effects of risk group and early marrow response, genetic abnormalities are known to have a strong effect on prognosis in precursor-B-cell ALL. This study evaluated the rate of end-of-induction MRD in a large number of patients in which PCR or FISH was used to identify the most important genetic abnormalities in ALL. Not surprisingly, most patients with Ph+ ALL were MRD+ at high levels, in agreement with other works that noted that Ph+ patients are virtually always MRD+ at the end of induction. 1 The presence of the TEL-AML1 translocation and hyperdiploidy involving trisomies 4 and 10 have both been associated with good outcome. 37, 38, 45 In this regard, finding a very low rate of MRD positivity among TEL+ patients is not surprising. Only 8% of patients had 40.01% MRD positivity at the end of induction, and less than 3% had 40.1%. Others have noted a similar trend, with smaller numbers. 1 Patients with TEL translocations also have been shown to be rapid early responders with conventional therapy. 46 Although it is possible that some of the patients with this translocation who relapse might correspond to the few patients who are MRD+, this seems unlikely, especially since many relapses appear to occur late in TEL-AML1 ALL. [47] [48] [49] Thus, the mechanism of relapse in this genetically defined subgroup may be different and not due to persistence of disease at the end of induction therapy. Additional studies using DNA microarray technology are in progress in the hopes of identifying novel markers of relapse in this patient subgroup.
The situation with favorable trisomies is quite different. These patients have long-term event-free survival (EFS) of 90%, with nearly 95% EFS at 3 years 38 (Sutcliffe, submitted for publication). In spite of an outcome that is as good or better than the favorable outcome of the TEL+ patients, these patients have a two-to three-fold higher incidence of MRD positivity at either the 0.1 or 0.01% levels, with more than 20% of patients positive. Pending longer follow-up, we do not know whether favorable trisomy patients with high MRD levels at the end of induction have a higher risk of relapse than those without. It is also possible that the kinetics of response in this subgroup is different, and that a later time point might better help to identify patients at risk for relapse. However, it is clear from results of previous trials that early intensification for all patients with favorable trisomies, who are MRD+ at the end of induction, would be overtreatment for a large portion of such individuals.
Our overall incidence of end-of-induction MRD is lower than that seen in the largest published series using molecular methodology.
14 There are several reasons that this might be so. First, the assumptions used in quantitation are very different between methods. What is called 0.01% by flow cytometry may not be the same as 0.01% by PCR. More significantly, we routinely exclude apoptotic cells from analysis based on lightscatter gating, while DNA-based methods will include the DNA of those cells. We, of course, do not know which is 'correct,' but it is not surprising that there is a difference.
The largest flow-cytometry-based series also shows a slightly higher end-of-induction MRD rate than we see here, 1 although both the therapy and timing of end-of-induction sampling in that protocol are very different from what we have employed. A more recent, smaller series, using three-or four-drug induction comparable to what we used 9 also showed an MRD+ rate that was much higher, while another recent small series was comparable or lower. 12 Confounding interpretation are varying proportions of patients in different risk groups, especially T-cell ALL, which were excluded from our series but are present in others; patients with T-ALL have been shown to have a higher incidence of MRD positivity than precursor-B ALL patients. 50 Nevertheless, we recognize that it is possible that in our study, in which more than 100 institutions obtain bone marrow and ship samples, there could be variability of technique in obtaining bone marrow. This is further magnified in our studies, in which up to 8 ml of marrow are obtained, for flow and molecular MRD studies as well as cell banking. Thus, it is possible that there may be blood contamination in some of our specimens. However, although this could potentially produce false negatives, a positive finding would still be useful to identify patients who might benefit from enhancement of therapy. Study designs to identify patients to receive less therapy on the basis of lack of MRD should be designed in such a way that the 'first pull' marrow is used for MRD assessment.
Owing to the potential problem of blood contamination of marrow, it would be desirable if MRD studies could be performed on the blood. However, definitive data on whether blood positivity can predict outcome do not yet exist. We found that only a small percentage of patients with marrow positivity are positive in the blood at day 29, and this is generally, although not invariably, at a much lower level, thus requiring higher sensitivity methods to detect positive patients. Others have found similarly that blood MRD levels do not match those of marrow in precursor-B-cell ALL. [51] [52] [53] In a small series of patients those with positive findings in blood at end induction had a very high risk of relapse. 53 Our data need further maturation to correlate blood end-of-induction results and outcome. On the other hand, detection of very rapid clearance of MRD from the blood might be useful to anticipate leukemia regression in marrow. For this reasons, we also investigated day 8 blood MRD by flow cytometry. Far too many patients are positive in the blood at day 8 by flow cytometry for it to be possible to use simple persistence of leukemic blasts as an indicator for early intervention, although some higher value cutoff might turn out to be more predictive of relapse. We also found interesting correlations between day 8 blood flow cytometry and morphologic measures of early marrow response, particularly as they relate to finding end-of-induction marrow MRD. Specifically, patients who are negative by flow cytometry at day 8 are almost never MRD+ at day 29, even if they are slow early responders. It is thus possible that day 8 blood flow could be used to identify patients who might benefit from, or might not need, a marrow examination. Our future plans include day 15 marrow examinations in some patients to help define early marrow response. Patients who are negative by flow at day 8 may not need this marrow examination.
